Breaking Finance News

Avacta Group PLC (LON:AVCT) price target upped to 200.00GBX, released a report earlier today by finnCap

Yesterday Avacta Group PLC (LON:AVCT) traded 1.12% higher at 89.00GBX. The company’s 50-day moving average is 97.06GBX and its 200-day moving average is 100.68GBX. The last stock close price is down -10.61% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 24,743 shares of the stock were exchanged, up from an average trading volume of 21,490

Reporting a potential upside of 1.25%, finnCap upped the price target of Avacta Group PLC (LON:AVCT) to 200.00GBX

See Chart Below

Avacta Group PLC (LON:AVCT)

Avacta Group PLC has a 52 week low of 83.02GBX and a 52 week high of 141.50GBX The company’s market cap is currently 0 GBX.

Also covering Avacta Group PLC's target, a total of 1 equity analyst has released a research note on AVCT. The one year target is 160.00GBX with zero equity analysts rating the company a strong buy, 0 brokers rating the stock a buy, 0 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 firms rating the stock a sell.

About Avacta Group PLC (LON:AVCT)

Avacta Group plc is the developer of Affimer bio therapeutics and research reagents. The Company's segments include Animal Health, which provides tools and contract services to assist diagnosis of conditions in animals to enable treatment for veterinarians, and Life Sciences, which provides reagents and arrays for diagnostics, drug and biomarker discovery in biotech research and development. The Company's in-house programs include Oncology, which is engaged in developing combination therapies combining multiple immune checkpoint inhibitors by making bi- and tri-specific Affimer constructs, and Blood clotting disorders, which allows Affimer therapeutics to generate the modulate blood clot formation with the potential for anti-thrombotic, as well as wound healing therapies. It focuses on its Affimer technology, which is an engineered alternative to antibodies that has application in Life Sciences for diagnostics, therapeutics and general research and development.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.